MCID: PPL002
MIFTS: 47

Papillary Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Papillary Carcinoma

MalaCards integrated aliases for Papillary Carcinoma:

Name: Papillary Carcinoma 12 14
Carcinoma, Papillary 42 69
Papillary Carcinoma Nos 12
Carcinoma Papillary 52

Classifications:



External Ids:

Disease Ontology 12 DOID:3113
MeSH 42 D002291
NCIt 47 C2927
SNOMED-CT 64 189562005 25910003
UMLS 69 C0007133

Summaries for Papillary Carcinoma

Disease Ontology : 12 A carcinoma that is derives from epithelial cells with finger like projections.

MalaCards based summary : Papillary Carcinoma, also known as carcinoma, papillary, is related to renal cell carcinoma, papillary and struma ovarii. An important gene associated with Papillary Carcinoma is TG (Thyroglobulin), and among its related pathways/superpathways are Endometrial cancer and Insulin secretion. The drugs Sunitinib and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include thyroid, kidney and lymph node, and related phenotypes are cellular and homeostasis/metabolism

Related Diseases for Papillary Carcinoma

Diseases related to Papillary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 306)
id Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, papillary 31.4 KRT7 MET PAX8
2 struma ovarii 30.4 KRT20 MUC1 PGR
3 fibroma 30.1 BRAF KRT20 MUC1
4 chondroblastoma 30.0 KRT20 MUC1 NKX2-1
5 lymphoma 29.6 TG TPO TSHR
6 peritoneal mesothelioma 25.2 BRAF CALCA KRT19 LGALS3 NCOA4 NKX2-1
7 breast papillary carcinoma 12.0
8 tall cell variant papillary carcinoma 11.9
9 ovary papillary carcinoma 11.9
10 primary peritoneal serous/papillary carcinoma 11.9
11 gallbladder papillary carcinoma 11.8
12 kidney pelvis papillary carcinoma 11.8
13 familial renal papillary carcinoma 11.8
14 bladder urothelial papillary carcinoma 11.8
15 papillary carcinoma of the cervix uteri 11.8
16 columnar cell variant papillary carcinoma 11.7
17 penis papillary carcinoma 11.7
18 papillary carcinoma of the corpus uteri 11.7
19 primary peritoneal carcinoma 11.7
20 renal cell carcinoma 11.2
21 2q31.1 microdeletion syndrome 11.0 BRAF MUC1
22 thyroid cancer, nonmedullary, 1 11.0
23 thyroid cancer, nonmedullary, 2 10.9
24 papillary squamous carcinoma 10.9
25 childhood mediastinal neurogenic tumor 10.8 CALCA TG
26 bladder tuberculosis 10.8 ERBB2 TG
27 thyroiditis 10.8
28 bile duct mucoepidermoid carcinoma 10.8 MUC1 PGR
29 laryngeal neuroendocrine tumor 10.8 BRAF MUC1
30 eccrine acrospiroma 10.8 KRT19 KRT7
31 gastritis 10.8 ERBB2 PGR
32 corneal ectasia 10.8 CALCA TG
33 breast cystic hypersecretory carcinoma 10.8 KRT19 KRT7
34 prostaglandin-endoperoxide synthase deficiency 10.8 KRT19 KRT7
35 glaucoma, hereditary 10.8 ERBB2 PGR
36 papillary serous adenocarcinoma 10.8
37 papillary thymic adenocarcinoma 10.8
38 nonencapsulated sclerosing carcinoma 10.8
39 peritoneal serous papillary adenocarcinoma 10.8
40 cervix erosion 10.8 KRT19 KRT7
41 cervical endometrial stromal sarcoma 10.7 CALCA TG
42 tmem38b-related osteogenesis imperfecta 10.7 BRAF ERBB2 RET
43 urinary bladder inverted papilloma 10.7 KRT19 PGR
44 trachea adenoid cystic carcinoma 10.7 KRT19 KRT7
45 skin sarcoma 10.7 ERBB2 PGR
46 her2-receptor negative breast cancer 10.7 ERBB2 PGR
47 congenital granular cell tumor 10.7 CALCA TG
48 spinal cancer 10.7 ERBB2 PGR
49 sohval soffer syndrome 10.7 BRAF ERBB2 MUC1
50 bile duct mucinous adenocarcinoma 10.7 KRT19 KRT7

Graphical network of the top 20 diseases related to Papillary Carcinoma:



Diseases related to Papillary Carcinoma

Symptoms & Phenotypes for Papillary Carcinoma

MGI Mouse Phenotypes related to Papillary Carcinoma:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 BRAF ERBB2 KRT19 KRT7 LGALS3 MET
2 homeostasis/metabolism MP:0005376 10.22 NCOA4 NKX2-1 PAX8 PGR RET TG
3 endocrine/exocrine gland MP:0005379 10.17 BRAF ERBB2 KRT19 MET NKX2-1 PAX8
4 cardiovascular system MP:0005385 10.15 BRAF ERBB2 KRT19 LGALS3 MET NKX2-1
5 digestive/alimentary MP:0005381 10 BRAF ERBB2 KRT19 LGALS3 MET NKX2-1
6 neoplasm MP:0002006 9.97 PGR RET TSHR BRAF ERBB2 KRT19
7 nervous system MP:0003631 9.96 BRAF ERBB2 KRT19 LGALS3 MET NKX2-1
8 limbs/digits/tail MP:0005371 9.91 ERBB2 MET PAX8 PGR RET TPO
9 normal MP:0002873 9.76 PAX8 PGR RET BRAF ERBB2 KRT19
10 reproductive system MP:0005389 9.65 BRAF CLDN3 ERBB2 KRT19 LGALS3 NKX2-1
11 skeleton MP:0005390 9.28 BRAF ERBB2 KRT19 LGALS3 NKX2-1 PAX8

Drugs & Therapeutics for Papillary Carcinoma

Drugs for Papillary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 184)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 3,Phase 2 341031-54-7, 557795-19-4 5329102
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
4
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177
5
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
6
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 5284616 6436030 46835353
7
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
8
Valrubicin Approved Phase 3,Phase 2 56124-62-0 41744
9
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
10
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
11
BCG vaccine Investigational Phase 3,Phase 2
12
Iodine Investigational Phase 2, Phase 3,Phase 1 7553-56-2 807
13
Doxil Approved June 1999 Phase 3 31703
14 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
15 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
16 Hormones Phase 2, Phase 3
17 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
18 Antimitotic Agents Phase 3,Phase 2,Phase 1
19 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
20 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
21 Adjuvants, Immunologic Phase 3,Phase 2
22 Vaccines Phase 3,Phase 2
23 Anti-Infective Agents Phase 2, Phase 3, Phase 1
24 Anti-Infective Agents, Local Phase 2, Phase 3,Phase 1
25 cadexomer iodine Phase 2, Phase 3,Phase 1
26 Micronutrients Phase 2, Phase 3,Phase 1
27 Trace Elements Phase 2, Phase 3,Phase 1
28 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
29 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
30 Keyhole-limpet hemocyanin Phase 3
31 Topoisomerase Inhibitors Phase 3,Phase 2
32 Antifungal Agents Phase 2, Phase 3,Phase 1
33 Hormone Antagonists Phase 2, Phase 3
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
35 Immunosuppressive Agents Phase 2, Phase 3, Phase 1
36 Alkylating Agents Phase 2, Phase 3
37 Antimetabolites Phase 2, Phase 3,Phase 1
38 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
39 Antiviral Agents Phase 2, Phase 3,Phase 1
40 Aromatase Inhibitors Phase 2, Phase 3
41 Estrogen Antagonists Phase 2, Phase 3
42 Estrogens Phase 2, Phase 3
43 Steroid Synthesis Inhibitors Phase 2, Phase 3
44 interferons Phase 2, Phase 3
45 Mitomycins Phase 2, Phase 3
46
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
47
Cimetidine Approved Phase 2 51481-61-9 2756
48
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
49
Diphenhydramine Approved Phase 2 58-73-1, 147-24-0 3100
50
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774

Interventional clinical trials:

(show top 50) (show all 149)

id Name Status NCT ID Phase Drugs
1 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
2 Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC Completed NCT01137097 Phase 2, Phase 3
3 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
4 Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer Completed NCT01083550 Phase 2, Phase 3
5 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Completed NCT00795782 Phase 3
6 Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer Completed NCT00006034 Phase 3 doxorubicin hydrochloride
7 Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
8 Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Recruiting NCT01149161 Phase 2, Phase 3
9 Savolitinib vs. Sunitinib in MET-driven PRCC Recruiting NCT03091192 Phase 3 Savolitinib;Sunitinib
10 Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG Recruiting NCT02449239 Phase 3
11 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
12 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
13 Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder Terminated NCT01310803 Phase 3 VALSTAR - Maintenance Therapy
14 Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer Terminated NCT01438112 Phase 2, Phase 3
15 Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer Terminated NCT00042887 Phase 3 mitomycin C
16 Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer Unknown status NCT00541008 Phase 2 sunitinib malate
17 Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer Unknown status NCT00786552 Phase 2 pemetrexed + paclitaxel
18 RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe Completed NCT00688753 Phase 2 RAD001
19 RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe Completed NCT00688623 Phase 2 Everolimus
20 Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer Completed NCT00867503 Phase 2 Bendamustine HCL
21 Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Completed NCT00559949 Phase 2 Selumetinib
22 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00729157 Phase 2
23 Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
24 A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) Completed NCT00726323 Phase 2 foretinib (formerly GSK1363089 or XL880)
25 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
26 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
27 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
28 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
29 Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer Completed NCT00022620 Phase 2 paclitaxel
30 Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery Completed NCT01688973 Phase 2 Erlotinib Hydrochloride;Tivantinib
31 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2 Bortezomib
32 Uterine Papillary Serous Cancer (UPSC) Trial Completed NCT00147680 Phase 2 Paclitaxel, Carboplatin
33 Study to Evaluate Safety and Biological Activity of TroVax® Vaccine Given in Conjunction With IL-2 to Treat Locally Advanced or Metastatic Renal Cell Carcinoma Completed NCT00325507 Phase 2
34 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2 Fostamatinib disodium
35 Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine Completed NCT00098813 Phase 2 romidepsin
36 Thalidomide in Treating Patients With Thyroid Cancer Completed NCT00026533 Phase 2 thalidomide
37 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer Completed NCT00542490 Phase 2
38 Chemotherapy in Treating Patients With Early-Stage Bladder Cancer Completed NCT00003129 Phase 2 valrubicin
39 Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer Completed NCT00459875 Phase 2 sunitinib malate
40 Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection Completed NCT00630214 Phase 2
41 Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer Completed NCT00251316 Phase 2 Lithium Carbonate;Placebo
42 pazopanib_NCRCC,Ph2 STUDY Completed NCT01538238 Phase 2 pazopanib
43 Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer Completed NCT00060307 Phase 2 erlotinib hydrochloride
44 Bortezomib in Treating Patients With Metastatic Kidney Cancer Completed NCT00276614 Phase 2 bortezomib
45 Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer Completed NCT00401128 Phase 2 gemcitabine hydrochloride;irinotecan hydrochloride
46 Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Completed NCT00118248 Phase 2 tanespimycin
47 Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma Completed NCT01108445 Phase 2 Everolimus;Sunitinib
48 A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation Completed NCT01286753 Phase 2 Vemurafenib
49 Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery Completed NCT00459979 Phase 2 sunitinib malate
50 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer Completed NCT00027573 Phase 2 cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus

Search NIH Clinical Center for Papillary Carcinoma

Cochrane evidence based reviews: carcinoma, papillary

Genetic Tests for Papillary Carcinoma

Anatomical Context for Papillary Carcinoma

MalaCards organs/tissues related to Papillary Carcinoma:

39
Thyroid, Kidney, Lymph Node, Lung, Liver, Breast, Skin

Publications for Papillary Carcinoma

Articles related to Papillary Carcinoma:

(show top 50) (show all 763)
id Title Authors Year
1
Subclonal analysis in a lobular breast cancer with classical and solid growth pattern mimicking a solid-papillary carcinoma. ( 28770103 )
2017
2
Impact of the Reclassification of the Non-Invasive Follicular Variant of Papillary Carcinoma as Benign on the Malignancy Risk of the Bethesda System for Reporting Thyroid Cytopathology: A Meta-Analysis Study. ( 28445876 )
2017
3
Warthin-like variant of thyroid papillary carcinoma. ( 28923670 )
2017
4
Anaplastic Spindle Cell Squamous Carcinoma Arising from Tall Cell Variant Papillary Carcinoma of the Thyroid Gland: A Case Report and Review of the Literature. ( 28484653 )
2017
5
Papillary Carcinoma Arising in a Thyroglossal Duct Cyst. ( 28492409 )
2017
6
Treatment of a giant pulmonary emphysematous cyst with primary bronchoalveolar papillary carcinoma in a Shih Tzu dog. ( 27898174 )
2017
7
Cytodiagnosis of papillary carcinoma of the male breast: Report of a case with histological correlation. ( 28469321 )
2017
8
Infiltrating Ductal Carcinoma Co-Existing with Intraductal Papillary Carcinoma of Male Breast: A Rare Case Report. ( 28764176 )
2017
9
A potential role for the Hippo pathway protein, YAP, in controlling proliferation, cell cycle progression, and autophagy in BCPAP and KI thyroid papillary carcinoma cells. ( 28804541 )
2017
10
Expression of nm23-H1 and COX-2 in thyroid papillary carcinoma and microcarcinoma. ( 28521457 )
2017
11
Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma. ( 28789361 )
2017
12
Defining Papillary Carcinoma of the Thyroid: A Short Review and Analysis. ( 28898991 )
2017
13
Evaluation of the presence of Epstein-Barr virus (EBV) in Iranian patients with thyroid papillary carcinoma. ( 28554750 )
2017
14
Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation. ( 28731042 )
2017
15
Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory BehAset disease uveitis and concomitant bladder papillary carcinoma. ( 28891187 )
2017
16
An Indian Tertiary Care Hospital Scenario of Papillary Carcinoma of Thyroid. ( 28764174 )
2017
17
Papillary carcinoma of the thyroid in patients with primary hyperparathyroidism: Is there a link? ( 28571792 )
2017
18
The relationship between the expressions of tumor associated fibroblasts Cav-1 and MCT4 and the prognosis of papillary carcinoma of breast. ( 28625953 )
2017
19
18F-FDG PET/CT of Papillary Carcinoma in a Lateral Thyroglossal Duct Cyst. ( 28525461 )
2017
20
Thyroid cancer: Overdiagnosis of papillary carcinoma - who benefits? ( 28059158 )
2017
21
Long-term outcome of thyroid lobectomy for unilateral multifocal papillary carcinoma. ( 28682915 )
2017
22
Papillary carcinoma in struma ovarii. ( 28251552 )
2017
23
Renal metastasis from papillary carcinoma thyroid detected by whole body iodine scan: A case report and review of the literature. ( 27385900 )
2016
24
Clinicopathological Characteristics and Survival Outcomes in Invasive Papillary Carcinoma of the Breast: A SEER Population-Based Study. ( 27053333 )
2016
25
BONE FUNCTIONING METASTASES REVELING A PAPILLARY CARCINOMA OF THE THYROID. ( 27363445 )
2016
26
Papillary Carcinoma of Thyroid Gland in a Two-year-old Child. ( 27081805 )
2016
27
Solid papillary carcinoma of the breast: A special entity needs to be distinguished from conventional invasive carcinoma avoiding over-treatment. ( 27017244 )
2016
28
Risk Factors of Lymphnode Metastasis in Patients with Thyroid <br/>Papillary Carcinoma Associated with Graves Disease. ( 27825413 )
2016
29
Expression of cancer-associated fibroblast-related proteins in thyroid papillary carcinoma. ( 26715280 )
2016
30
The risk of hypoparathyroidism after central compartment lymph node dissection in the surgical treatment of pT1, N0 thyroid papillary carcinoma. ( 27212170 )
2016
31
An analysis of trends of incidence and cytohistological correlation of papillary carcinoma of the thyroid gland with evaluation of discordant cases. ( 28028333 )
2016
32
Papillary carcinoma in thyroglossal duct cyst: Two case reports and review of the literature. ( 26991228 )
2016
33
A rare case of papillary carcinoma of thyroid presenting as a lung mass. ( 27728572 )
2016
34
De novo papillary carcinoma in a renal allograft: the pros and cons of immunosuppression. ( 28509174 )
2016
35
Renal cell carcinoma in kidney allografts: histologic types, including biphasic papillary carcinoma. ( 27396934 )
2016
36
Dual malignancy in adolescence: A rare case report of metachronous papillary carcinoma of thyroid following dysgerminoma of ovary. ( 27904567 )
2016
37
Activating BRAF Mutations Detected in Mixed HA1rthle Cell Carcinoma and Multifocal Papillary Carcinoma of the Thyroid Gland: Report of an Unusual Case and Review of the Literature. ( 27006301 )
2016
38
Hashimoto's thyroiditis and papillary carcinoma in an adolescent girl: A case report. ( 27330783 )
2016
39
Vitamin D receptor expression is linked to potential markers of human thyroid papillary carcinoma. ( 26907966 )
2016
40
Papillary carcinoma of the breast: diagnostic agreement and management implications. ( 27270947 )
2016
41
CT-detected solitary thyroid calcification: an important imaging feature for papillary carcinoma. ( 27785075 )
2016
42
Can Sentinel Lymph Node Biopsy Be Spared in Papillary Carcinoma of the Breast? ( 27692774 )
2016
43
Encapsulated papillary carcinoma (EPC) of breast: A clinical, pathological and immunohistochemical analysis of eight cases. ( 27812076 )
2016
44
Primary Squamous Cell Carcinoma of Trachea Arising 4 Years After Radioiodine Treatment of Papillary Carcinoma of Thyroid. ( 26828143 )
2016
45
A case of minocycline-induced black thyroid associated with papillary carcinoma. ( 26991226 )
2016
46
Follicular Variant of Papillary Carcinoma Arising in Struma Ovarii. ( 27190936 )
2016
47
Eyelid Metastatic Thyroid Papillary Carcinoma. ( 27239457 )
2016
48
The prognostic significance of hematological parameters in women with uterine serous papillary carcinoma (USPC). ( 26894377 )
2016
49
Intracystic papillary carcinoma of the breast: A SEER database analysis of implications for therapy. ( 27054753 )
2016
50
Systemic paraneoplastic vasculitis secondary to papillary carcinoma of the thyroid. ( 27416971 )
2016

Variations for Papillary Carcinoma

Expression for Papillary Carcinoma

Search GEO for disease gene expression data for Papillary Carcinoma.

Pathways for Papillary Carcinoma

GO Terms for Papillary Carcinoma

Biological processes related to Papillary Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.97 BRAF CLDN3 ERBB2 MET PGR RET
2 MAPK cascade GO:0000165 9.62 BRAF ERBB2 MET RET
3 hormone biosynthetic process GO:0042446 9.26 TG TPO
4 positive regulation of adenylate cyclase activity GO:0045762 9.16 CALCA TSHR
5 thyroid-stimulating hormone signaling pathway GO:0038194 8.96 PAX8 TSHR
6 thyroid gland development GO:0030878 8.92 BRAF NKX2-1 PAX8 TG

Molecular functions related to Papillary Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 ERBB2 MET RET
2 thyroid-stimulating hormone receptor activity GO:0004996 8.62 PAX8 TSHR

Sources for Papillary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....